NAYA Biosciences (NASDAQ: NAYA) has seen a decline in its stock price by -29.93 in relation to its previous close of 0.32. However, the company has experienced a -27.42% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-13 that SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) — NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company’s common stock will trade on a post-split basis under the same trading symbol, “NAYA”.
Is It Worth Investing in NAYA Biosciences (NASDAQ: NAYA) Right Now?
Moreover, the 36-month beta value for NAYA is 1.80. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAYA is 5.98M and currently, short sellers hold a 1.68% of that float. On March 14, 2025, NAYA’s average trading volume was 175.78K shares.
NAYA’s Market Performance
NAYA stock saw a decrease of -27.42% in the past week, with a monthly decline of -37.50% and a quarterly a decrease of -71.16%. The volatility ratio for the week is 9.34%, and the volatility levels for the last 30 days are 10.04% for NAYA Biosciences (NAYA). The simple moving average for the last 20 days is -34.06% for NAYA stock, with a simple moving average of -69.27% for the last 200 days.
NAYA Trading at -51.69% from the 50-Day Moving Average
After a stumble in the market that brought NAYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.57% of loss for the given period.
Volatility was left at 10.04%, however, over the last 30 days, the volatility rate increased by 9.34%, as shares sank -36.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -70.98% lower at present.
During the last 5 trading sessions, NAYA fell by -26.52%, which changed the moving average for the period of 200-days by -74.40% in comparison to the 20-day moving average, which settled at $0.3414. In addition, NAYA Biosciences saw -72.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NAYA
Current profitability levels for the company are sitting at:
- -0.91 for the present operating margin
- 0.42 for the gross margin
The net margin for NAYA Biosciences stands at -1.2. The total capital return value is set at -0.68. Equity return is now at value -14358.50, with -57.44 for asset returns.
Based on NAYA Biosciences (NAYA), the company’s capital structure generated 1.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.58. The debt to equity ratio resting at -228.82. The interest coverage ratio of the stock is -5.62.
Currently, EBITDA for the company is -6.88 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 1.04. The receivables turnover for the company is 24.23for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.30.
Conclusion
To wrap up, the performance of NAYA Biosciences (NAYA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
